Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | IV daratumumab in R/R myeloma: bodyweight analysis

Maria-Victoria Mateos • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Daratumumab
COLUMBA

Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the Phase III COLUMBA (NCT03277105) study evaluating subcutaneous intravenous (IV) daratumumab in relapsed/refractory (R/R) multiple myeloma patients, specifically discussed is the results of the bodyweight subgroup analysis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals